64Cu-DOTATATE for noninvasive assessment of atherosclerosis in large arteries and its correlation with risk factors: Head-to-head comparison with 68Ga-DOTATOC in 60 patients

Journal of Nuclear Medicine

Volumn 56, Issue 12, 2015, Pages 1895-1900

  Malmberg, Catarina ^a   Ripa, Rasmus S ^a   Johnbeck, Camilla B ^a   Knigge, Ulrich ^b   Langer, Seppo W ^b   Mortensen, Jann ^a   Oturai, Peter ^a   Loft, Annika ^a   Hag, Anne Mette ^a   Kjer, Andreas ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

Atherosclerosis; Macrophages; Molecular imaging; PET CT; Somatostatin receptor

Indexed keywords

OCTREOTATE TETRAXETAN CU 64; OCTREOTIDE TETRAXETAN GA 68; TRACER; UNCLASSIFIED DRUG; 64CU-DOTATATE; CALCIUM; GA(III)-DOTATOC; OCTREOTIDE; ORGANOMETALLIC COMPOUND; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR RISK; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CORONARY ARTERY CALCIUM SCORE; DIABETES MELLITUS; FEMALE; FRAMINGHAM RISK SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NEUROENDOCRINE TUMOR; NON INVASIVE PROCEDURE; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; RISK ASSESSMENT; SMOKING; STANDARDIZED UPTAKE VALUE; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; AORTA; ARTERY; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; COMPARATIVE STUDY; CORONARY BLOOD VESSEL; IMAGE PROCESSING; METABOLISM; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; RISK FACTOR; SCINTISCANNING; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AORTA; ARTERIES; ATHEROSCLEROSIS; BODY MASS INDEX; CALCIUM; CARDIOVASCULAR DISEASES; CORONARY VESSELS; DIABETES MELLITUS; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RISK FACTORS; SMOKING;

EID: 84958236781     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.161216     Document Type: Article

References (31)

1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-126.
2. Davies JR, Rudd JH, Weissberg PL. Molecular and metabolic imaging of atherosclerosis. J Nucl Med. 2004;45:1898-1907.
3. Gallino A, Stuber M, Crea F, et al. "In vivo" imaging of atherosclerosis. Atherosclerosis. 2012;224:25-36.
4. 68Ga-DOTATATE autoradiographic, immunohistochemical and flow cytometric studies in apoE-deficient mice. Atherosclerosis. 2013;230:33-39.
5. Armani C, Catalani E, Balbarini A, Bagnoli P, Cervia D. Expression, pharmacology, and functional role of somatostatin receptor subtypes 1 and 2 in human macrophages. J Leukoc Biol. 2007;81:845-855.
6. 68Ga-DOTATATE PET/CT: correlation with coronary calcium burden and risk factors. J Nucl Med. 2010;51:193-197.
7. Reubi JC, Schar JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scinti-graphic and radiotherapeutic use. Eur J Nucl Med. 2000;27:273-282.
8. Schatka I, Wollenweber T, Haense C, Brunz F, Gratz KF, Bengel FM. Peptide receptor-targeted radionuclide therapy alters inflammation in atherosclerotic plaques. J Am Coll Cardiol. 2013;62:2344-2345.
9. 64Cu-DOTATATE PET/MR for detection of activated macrophages in carotid atherosclerotic plaques: studies in patients undergoing endarterectomy. Arterioscler Thromb Vasc Biol. 2015;35: 1696-1703.
10. 68Ga-radiopharmaceutical development. Theranostics. 2013;4:47-80.
11. Rice SL, Roney CA, Daumar P, Lewis JS. The next generation of positron emission tomography radiopharmaceuticals in oncology. Semin Nucl Med. 2011;41: 265-282.
12. Li Z, Conti PS. Radiopharmaceutical chemistry for positron emission tomography. Adv Drug Deliv Rev. 2010;62:1031-1051.
13. 68Ga-PET: a powerful generator-based alternative to cyclotron-based PET radiopharmaceuticals. Contrast Media Mol Imaging. 2008;3:67-77.
14. Wadas TJ, Wong EH, Weisman GR, Anderson CJ. Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem Rev. 2010;110:2858-2902.
15. D'Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117: 743-753.
16. Yun M, Yeh D, Araujo LI, Jang S, Newberg A, Alavi A. F-18 FDG uptake in the large arteries: a new observation. Clin Nucl Med. 2001;26:314-319.
17. 18F]-fluorodeoxyglucose positron emission tomography. Circulation. 2002;105:2708-2711.
18. Pedersen SF, Graebe M, Fisker Hag AM, Hojgaard L, Sillesen H, Kjaer A. Gene expression and 18FDG uptake in atherosclerotic carotid plaques. Nucl Med Commun. 2010;31:423-429.
19. Graebe M, Pedersen SF, Borgwardt L, Hojgaard L, Sillesen H, Kjaer A. Molecular pathology in vulnerable carotid plaques: correlation with [18]-fluorodeoxyglucose positron emission tomography (FDG-PET). Eur J Vasc Endovasc Surg. 2009;37:714-721.
20. 18F-FDG PET imaging of murine atherosclerosis: association with gene expression of key molecular markers. PLoS One. 2012;7:e50908.
21. 18F-FDG imaging of human atherosclerotic carotid plaques reflects gene expression of the key hypoxia marker HIF-1alpha. Am J Nucl Med Mol Imaging. 2013;3:384-392.
22. 18F FDG uptake in the large arteries: a correlation study with the atherogenic risk factors. Semin Nucl Med. 2002;32:70-76.
23. Camici PG, Rimoldi OE, Gaemperli O, Libby P. Non-invasive anatomic and functional imaging of vascular inflammation and unstable plaque. Eur Heart J. 2012;33:1309-1317.
24. 64Cu-DOTATATE: first-in-humans study. J Nucl Med. 2012;53:1207-1215.
25. 68Ga-DOTATATE: net uptake rate for accurate quantification. J Nucl Med. 2014;55:204-210.
26. Johnbeck CB, Knigge U, Kjaer A. PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature. Future Oncol. 2014;10:2259-2277.
27. 18F-FDG, calcium burden and risk factors. EJNMMI Res. 2012;2:52.
28. Yang J, Kan Y, Ge BH, Yuan L, Li C, Zhao W. Diagnostic role of gallium-68 DOTATOC and gallium-68 DOTATATE PET in patients with neuroendocrine tumors: a meta-analysis. Acta Radiol. 2014;55:389-398.
29. Randolph GJ. Mechanisms that regulate macrophage burden in atherosclerosis. Circ Res. 2014;114:1757-1771.
30. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
31. 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37:2004-2010.